RxDoctor Payments Data

Jane Luu, MD

Cardiovascular Disease · Portland, ORNPI 1124281423

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Abbott at 45.8% of the total. Reporting peaked in 2019 at $3,370 and has fallen 95.1% since, to $166 in 2025.

$3,927in general payments, 2019–2025

Across 53 payments — averaging $74.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$2K
  • Edwards Lifesciences$186
  • Teleflex LLC$120
  • Novartis$39
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30
  • plus $21 from 1 others

What the payments were for

  • Travel & lodging$2,19756%
  • Food & beverage$1,73144%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,927 in reported general payments places this provider in the 75th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$12,885
Medicare patients
68
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$106,221
EntrestoSacubitril/Valsartan49$38,722
XareltoRivaroxaban14$21,452
Ranolazine ErRanolazine14$3,109
Losartan Potassium212$1,805
Metoprolol Succinate166$1,435
Isosorbide Mononitrate ErIsosorbide Mononitrate40$787
ClopidogrelClopidogrel Bisulfate64$739
Amlodipine Besylate120$721
Atorvastatin Calcium90$715
Rosuvastatin Calcium40$605
Metoprolol Tartrate63$462
Lisinopril69$382
Carvedilol56$370
Furosemide57$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$39$38,72249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →